

SUPPORTING INFORMATION

Gold(I)-catalyzed Intermolecular Cycloaddition of Allenamides with α,β -Unsaturated Hydrazones: Efficient Access to Highly Substituted Cyclobutanes

Paloma Bernal-Albert,[†] Hélio Faustino,[†] Ana Gimeno,[§] Gregorio Asensio,[§] José L. Mascareñas^{†,*} and Fernando López^{†,‡,*}

[†] Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS) and Departamento de Química Orgánica. Universidad de Santiago de Compostela, 15782, Santiago de Compostela (Spain).

[‡] Instituto de Química Orgánica General CSIC, Juan de la Cierva 3, 28006, Madrid (Spain).

[§] Departamento de Química Orgánica. Universidad de Valencia, Avda. Vicent Andrés Estellés s/n 46100-Burjassot, Valencia (Spain)

Contents:


General Procedures	S3
Experimental data	S4
NMR Spectra	S21

General Procedures

Dry solvents were freshly distilled under argon from an appropriate drying agent before use. Dry THF was obtained using Solvent Purification System (SPS). Toluene and CH_2Cl_2 was purchased from Aldrich. Gold complex **Au1** was purchased from Aldrich. All other chemicals were purchased from Aldrich, TCI or Alfa Aesar and used without further purification, unless otherwise noted. Reactions were conducted in dry solvents under argon atmosphere unless otherwise stated. The abbreviation "rt" refers to reactions carried out approximately at 23°C. Reaction mixtures were stirred using Teflon-coated magnetic stirring bars. Reaction temperatures were maintained using Thermowatch-controlled silicone oil baths. Thin-layer chromatography (TLC) was performed on silica gel plates and components were visualized by observation under UV light, and / or by treating the plates with *p*-anisaldehyde or cerium nitrate solutions, followed by heating. Flash chromatography was carried out on silica gel unless otherwise stated. Dryings were performed with anhydrous Na_2SO_4 or MgSO_4 . Concentration refers to the removal of volatile solvents via distillation using a Büchi rotary evaporator followed by residual solvent removal under high vacuum. NMR spectra were recorded in CDCl_3 , at 250 MHz (Bruker), 300 MHz (Varian), 400 MHz (Varian) or 500 MHz (Varian) for cycloadducts. Carbon types and structure assignments were determined from DEPT-NMR and two-dimensional experiments (HMQC and HMBC, COSY and NOESY). NMR spectra were analyzed using MestreNova[®] NMR data processing software (www.mestrelab.com). The following abbreviations are used to indicate signal multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; dd, double doublet; td, triple doublet; m, multiplet; br, broad. Mass spectra were acquired using chemical ionization (CI) electron impact (EI), or electrospray ionization (ESI) and were recorded at the CACTUS facility of the University of Santiago de Compostela. The reactions were monitored by TLC or GC-MS using the Agilent Technologies 6890N, Network GC System, equipped with the Agilent 190915-433 column and the Agilent 5973 Inert Mass Selective Detector in Electron Impact or Chemical Ionization Mode (with Methane).

Experimental data

Experimental procedures for the synthesis of α,β -Unsaturated Hydrazones (2). Exemplified for the synthesis of **2a**



MgSO₄ (0.99 mg, 8.21 mmol) and *N,N*-diisopropylhydrazine (20.5 mmol, 2.4 g) were added to a solution of (*E*)-2-methyl-3-phenylacrylaldehyde (0.96 ml, 6.84 mmol) in CH₂Cl₂ (3.4 ml). After stirring at rt for 24h, the mixture was filtered, washed with brine (5 ml) and extracted (CH₂Cl₂, 2 x 10 ml). The combined organic phases were dried, filtered and evaporated to yield a crude oil that was purified by column chromatography (hexanes: EtOAc 8:2) to afford the hydrazone **2a** (1.48 g) in 89% yield. Yellow solid. (*1E,2E*)-2-Methyl-3-phenylacrylaldehyde diisopropylhydrazone. ¹H NMR (300 MHz, CDCl₃) δ 7.61 – 7.41 (m, 4H), 7.40 – 7.22 (m, 2H), 6.59 (s, 1H), 4.06 – 3.96 (m, 2H), 2.37 (d, *J* = 1.2 Hz, 3H), 1.36 (d, *J* = 6.5 Hz, 12H). ¹³C NMR (75 MHz, CDCl₃) δ 138.60 (C), 138.01 (C), 132.34 (CH), 128.96 (CH), 128.12 (CH), 127.44 (CH), 125.83 (CH), 47.47 (CH), 20.97 (CH₃), 13.59 (CH₃). LRMS (ESI): 245 (M⁺ + 1), 203, 161, 144, 118, 86; HRMS calculated for C₁₆H₂₅N₂ 245.2012, found 245.2010.

(*1E,2E*)-3-Phenylacrylaldehyde diisopropylhydrazone (**2b**)

2b Yellow oil, 83% yield. ¹H NMR (300 MHz, CDCl₃) δ 7.45 (d, *J* = 8.7 Hz, 2H), 7.32 (t, *J* = 7.6 Hz, 2H), 7.27 – 7.15 (m, 2H), 7.04 (dd, *J* = 15.9, 8.7 Hz, 1H), 6.50 (d, *J* = 15.9 Hz, 1H), 3.88 (hept, *J* = 6.6 Hz, 2H), 1.22 (d, *J* = 6.6 Hz, 12H). ¹³C NMR (75 MHz, CDCl₃) δ 138.05 (C), 129.43 (CH), 129.40 (CH), 128.43 (CH), 127.82 (CH), 126.46 (CH), 125.78 (CH), 47.49 (CH), 20.81 (CH₃). LRMS (ESI): 231 (M⁺ + 1), 203, 189, 173, 147, 132, 100, 86; HRMS calculated for C₁₅H₂₃N₂ 231.1856, found 231.1855.

(*1E,2E*)-3-(4-Methoxyphenyl)acrylaldehyde diisopropylhydrazone (**2c**)


2c Yellow solid, 87% yield. ¹H NMR (300 MHz, CDCl₃) δ 7.35 (d, *J* = 8.8 Hz, 2H), 7.20 (d, *J* = 8.7 Hz, 1H), 6.93 – 6.82 (m, 3H), 6.44 (d, *J* = 15.9 Hz, 1H), 3.89 – 3.81 (m, 2H), 3.81 (s, 3H), 1.19 (d, *J* = 6.6 Hz, 12H). ¹³C NMR (75 MHz, CDCl₃) δ 158.71 (C), 131.07 (C), 130.48 (CH), 128.02 (CH), 127.62 (CH), 127.16 (CH), 114.15 (CH), 55.38 (CH₃), 47.64 (CH), 20.99 (CH₃). LRMS (ESI): 261 (M⁺ + 1), 235, 219, 203, 177, 162, 135, 86; HRMS calculated for C₁₆H₂₅N₂O 261.1961, found 261.1957.

(*1E,2E*)-3-(4-Fluorophenyl)acrylaldehyde diisopropylhydrazone (**2d**)


2d White solid, 93% yield ¹H NMR (300 MHz, CDCl₃) δ 7.36 (dd, *J* = 8.4, 5.7 Hz, 2H), 7.17 (d, *J* = 8.7 Hz, 1H), 7.02 – 6.83 (m, 3H), 6.42 (d, *J* = 15.9 Hz, 1H), 3.85 (hept, *J* = 6.5 Hz, 2H), 1.19 (d, *J* = 6.5 Hz, 12H). ¹³C NMR (75 MHz, CDCl₃) δ 161.84 (d, *J* = 245.9 Hz, C), 134.47 (d, *J* = 3.0 Hz, C), 129.44 (d, *J* = 2.0 Hz, CH), 129.34 (CH), 127.32 (d, *J* = 7.7 Hz, CH), 126.71 (CH), 115.55 (d, *J* = 21.5 Hz,

CH), 47.73 (CH), 21.01 (CH₃). **LRMS** (ESI): 249 (M⁺ + 1), 165, 150, 123, 100, 86; **HRMS** calculated for C₁₅H₂₂N₂F 249.1762, found 249.1761.


(1*E*,2*E*)-2,3-Diphenylacrylaldehyde diisopropylhydrazone (**2e**).¹

 Yellow oil, 43% yield. **¹H NMR** (300 MHz, CDCl₃) δ 7.36 – 7.20 (m, 7H), 7.12 – 7.01 (m, 2H), 6.99 – 6.93 (m, 2H), 6.55 (s, 1H), 3.81 (hept, *J* = 6.5 Hz, 2H), 1.06 (d, *J* = 6.5 Hz, 12H). **LRMS** (ESI): 307 (M⁺ + 1), 282, 265, 206, 179, 163, 86; **HRMS** calculated for C₂₁H₂₇N₂ 307.2169, found 307.2178.


(1*E*,2*E*)-2-Methylbut-2-enal diisopropylhydrazone (**2f**)

 Yellow oil, 72% yield. **¹H NMR** (300 MHz, CDCl₃) δ 7.04 (s, 1H), 5.45 (q, *J* = 6.7 Hz, 1H), 3.73 (hept, *J* = 6.5 Hz, 2H), 1.84 (s, 3H), 1.74 (d, *J* = 7.0 Hz, 3H), 1.11 (d, *J* = 6.6 Hz, 12H). **¹³C NMR** (75 MHz, CDCl₃) δ 136.56 (C), 134.39 (CH), 123.53 (CH), 47.14 (CH), 20.74 (CH₃), 13.65 (CH₃), 11.48 (CH₃). **LRMS** (ESI): 183 (M⁺ + 1), 141, 125, 86; **HRMS** calculated for C₁₁H₂₃N₂ 183.1856, found 183.1853.


(1*E*,2*E*)-2-Phenylbut-2-enal diisopropylhydrazone (**2g**)

 Yellow oil, 37% yield. **¹H NMR** (300 MHz, CDCl₃) δ 7.47 – 7.20 (m, 6H), 5.82 (q, *J* = 7.2 Hz, 1H), 3.85 – 3.71 (m, 2H), 1.76 (d, *J* = 7.1 Hz, 3H), 1.08 (d, *J* = 6.5 Hz, 12H). **¹³C NMR** (126 MHz, CDCl₃) δ 130.45 (C), 130.41 (CH), 130.21 (CH), 128.30 (CH), 127.27 (CH), 126.26 (C), 125.93 (CH), 52.25 (CH), 20.86 (CH₃), 19.48 (CH₃). **LRMS** (ESI): 245 (M⁺ + 1), 203, 177, 161, 144, 118, 100, 86; **HRMS** calculated for C₁₆H₂₅N₂ 245.2012, found 245.2010.


(1*E*,2*E*)-But-2-enal diisopropylhydrazone (**2h**)

 Yellow oil, 77% yield. **¹H NMR** (300 MHz, CDCl₃) δ 7.04 (d, *J* = 8.7 Hz, 1H), 6.30 – 6.18 (m, 1H), 5.71 – 5.56 (m, 1H), 3.80 – 3.66 (m, 2H), 1.79 (dd, *J* = 6.8, 1.4 Hz, 3H), 1.12 (d, *J* = 6.6 Hz, 12H). **¹³C NMR** (75 MHz, CDCl₃) δ 131.90 (CH), 131.62 (CH), 126.25 (CH), 47.33 (CH), 20.83 (CH₃), 18.19 (CH₃). **LRMS** (ESI): 169 (M⁺ + 1), 127, 111, 100, 86; **HRMS** calculated for C₁₀H₂₁N₂ 169.1699, found 169.1697.

Cyclohex-1-ene-1-carbaldehyde diisopropylhydrazone (**2i**)

 Yellow oil, 83% yield. **¹H NMR** (300 MHz, CDCl₃) δ 7.03 (s, 1H), 5.71 – 5.64 (m, 1H), 3.75 (hept, *J* = 6.5 Hz, 2H), 2.37 – 2.30 (m, 2H), 2.20 – 2.10 (m, 2H), 1.70 – 1.60 (m, 4H), 1.13 (d, *J* = 6.6 Hz, 12H). **¹³C NMR** (75 MHz, CDCl₃) δ 137.80 (C), 132.76 (CH), 126.13 (CH), 47.09 (CH), 25.85 (CH₂), 24.22 (CH₂), 23.17 (CH₂), 22.67 (CH₂), 20.80 (CH₃). **LRMS** (ESI): 209 (M⁺ + 1), 167, 141, 125, 86. **HRMS** calculated for C₁₃H₂₅N₂ 209.2012, found 209.2007.


Cyclopent-1-ene-1-carbaldehyde diisopropylhydrazone (**2j**)

 Yellow oil, 69% yield. **¹H NMR** (300 MHz, CDCl₃) δ 7.26 (s, 1H), 5.65 – 5.59 (m, 1H), 3.79 (hept, *J* = 6.5 Hz, 2H), 2.61 (td, *J* = 7.7, 1.9 Hz, 2H), 2.51 – 2.39 (m, 2H), 1.95 – 1.84 (m, 2H), 1.15 (d, *J* = 6.5 Hz, 12H). **¹³C NMR** (126


¹ This product turned out to be unstable. It was immediately used after purification.

MHz, CDCl₃) δ 137.78 (C), 126.26, (CH), 125.80, (CH), 47.62 (CH), 32.85 (CH₂), 31.28 (CH₂), 22.98 (CH₂), 20.72 (CH₃). **LRMS** (ESI): 217 (M⁺ + Na), 209, 172, 115, 86; **HRMS** calculated for C₁₂H₂₂N₂Na 217.1675 found 217.1682.


Ethyl (2*E*, 4*E*)-4-(2,2-diisopropylhydrazono)-3-methylbut-2-enoate (**2k**)

 Yellow oil, 74% yield. **¹H NMR** (300 MHz, CDCl₃) δ 6.95 (s, 1H), 5.65 (s, 1H), 4.16 (q, *J* = 7.1 Hz, 2H), 3.93 – 3.80 (m, 2H), 2.39 (d, *J* = 1.1 Hz, 3H), 1.28 (t, *J* = 7.1 Hz, 3H), 1.19 (d, *J* = 6.5 Hz, 12H). **¹³C NMR** (75 MHz, CDCl₃) δ 168.02 (C), 155.32 (C), 128.13 (CH), 113.88 (CH), 59.39 (CH), 48.34 (CH₂), 21.09 (CH₃), 14.60 (CH₃), 13.56 (CH₃). **LRMS** (ESI): 241 (M⁺ + 1), 199, 153, 112, 100; **HRMS** calculated for C₁₃H₂₅N₂O₂ 241.1911, found 241.1910.


(1*E*,2*E*)-2-Methyl-3-phenylacrylaldehyde dimethylhydrazone (**2a'**)

 White solid, 74% yield. **¹H NMR** (500 MHz, CDCl₃) δ 7.43 – 7.36 (m, 4H), 7.29 – 7.24 (m, 1H), 7.19 (s, 1H), 6.58 (s, 1H), 2.95 (s, 6H), 2.20 (s, *J* = 1.3 Hz, 3H). **¹³C NMR** (126 MHz, CDCl₃) δ 139.17 (CH), 137.94 (C), 136.41 (C), 130.66 (CH), 129.14 (CH), 128.24 (CH), 126.49 (CH), 43.09 (CH₃), 13.50 (CH₃). **LRMS** (ESI): 189 (M⁺ + 1), 173, 146, 117, 91; **HRMS** calculated for C₁₂H₁₇N₂ 189.1386, found 189.1381.


(1*E*,2*E*)-3-Phenylacrylaldehyde dimethylhydrazone (**2b'**)

 Yellow solid, 99% yield. **¹H NMR** (500 MHz, CDCl₃) δ 7.45 (d, *J* = 8.0 Hz, 2H), 7.35 (t, *J* = 7.7 Hz, 2H), 7.24 (t, *J* = 7.3 Hz, 1H), 7.16 (d, *J* = 9.0 Hz, 1H), 7.04 – 6.97 (m, 1H), 6.64 (d, *J* = 15.9 Hz, 1H), 2.94 (s, 6H). **¹³C NMR** (126 MHz, CDCl₃) δ 137.31 (C), 135.07 (CH), 131.57 (CH), 128.62 (CH), 127.56 (CH), 127.33 (CH), 126.18 (CH), 42.70 (CH₃). **LRMS** (ESI): 175 (M⁺ + 1), 148, 132, 115; **HRMS** calculated for C₁₁H₁₅N₂ 175.1230, found 175.1228.

(1*E*,2*E*)-3-(4-Methoxyphenyl)acrylaldehyde dimethylhydrazone (**2c'**)

 Yellow solid, 93% yield. **¹H NMR** (500 MHz, CDCl₃) δ 7.36 – 7.33 δ 7.34 (d, *J* = 8.9 Hz, 2H), 7.14 (d, *J* = 8.9 Hz, 1H), 6.85 (d, *J* = 8.8 Hz, 2H), 6.81 (dd, *J* = 16.0, 8.9 Hz, 1H), 6.57 (d, *J* = 15.9 Hz, 1H), 3.79 (s, 3H), 2.89 (s, 6H). **¹³C NMR** (126 MHz, CDCl₃) δ 159.24 (C), 136.22 (CH), 131.76 (CH), 130.16 (C), 127.54 (CH), 125.57 (CH), 114.20 (CH), 55.35 (CH₃), 42.94 (CH₃). **LRMS** (ESI): 205 (M⁺ + 1), 178, 160, 133, 117, 90; **HRMS** calculated for C₁₂H₁₇N₂O 205.1335, found 205.1335.

(1*E*,2*E*)-2-Methylbut-2-enal dimethylhydrazone (**2f'**)

 Yellow oil, 72% yield. **¹H NMR** (300 MHz, CDCl₃) δ 6.95 (s, 1H), 5.54 (q, *J* = 6.7 Hz, 1H), 2.72 (s, 6H), 1.77 – 1.75 (m, 3H), 1.70 (dd, *J* = 7.0, 0.9 Hz, 3H). **¹³C NMR** (75 MHz, CDCl₃) δ 140.24 (CH), 135.24 (C), 126.99 (CH), 43.06 (CH₃), 13.67 (CH₃), 11.27 (CH₃). **LRMS** (ESI): 127 (M⁺ + 1), 111, 84; **HRMS** calculated for C₇H₁₅N₂ 127.1230, found 127.1235.

Ethyl (2E,4Z)-4-(2,2-dimethylhydrazono)-3-methylbut-2-enoate (**2k'**)

Yellow oil, 74% yield. ¹H NMR (500 MHz, CDCl₃) δ 6.74 (d, *J* = 6.1 Hz, 1H), 5.66 (d, *J* = 5.8 Hz, 1H), 4.13 – 4.04 (m, 2H), 2.94 – 2.88 (m, 6H), 2.29 – 2.24 (m, 3H), 1.23 – 1.17 (m, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 167.29 (C), 153.16 (C), 132.66 (CH), 116.25 (CH), 59.32 (CH₂), 42.30 (CH₃), 14.31 (CH₃), 13.19 (CH₃). LRMS (ESI): 185 (M⁺ + 1), 139, 111, 96; HRMS calculated for C₉H₁₆N₂O₂ 185.1285, found 185.1286.


(2S)-2-(Methoxymethyl)-N-[(1E,2E)-2-methyl-3-phenylprop-2-en-1-ylidene]pyrrolidin-1-amine (**2a''**)

Yellow oil, 67 % yield. ¹H NMR (300 MHz, CDCl₃) δ 7.39 – 7.35 (m, 4H), 7.26 – 7.18 (m, 1H), 7.15 (s, 1H), 6.50 (s, 1H), 3.70 – 3.58 (m, 2H), 3.54 – 3.45 (m, 2H), 3.42 (s, 3H), 3.01 (dd, *J* = 16.8, 7.9 Hz, 1H), 2.16 (d, *J* = 1.2 Hz, 3H), 2.12 – 1.84 (m, 4H). ¹³C NMR (75 MHz, CDCl₃) δ 138.61 (CH), 138.11 (C), 136.74 (C), 129.64 (CH), 129.05 (CH), 128.18 (CH), 126.27 (CH), 74.62 (CH₂), 63.19 (CH₃), 59.27 (CH), 49.12 (CH₂), 26.87 (CH₂), 22.28 (CH₂), 13.45 (CH₃). LRMS (ESI): 259 (M⁺ + 1), 227, 146, 114, 91; HRMS calculated for C₁₆H₂₃N₂O 259.1805, found 259.1803.

(2S)-2-(Methoxymethyl)-N-[(1E,2E)-2-methylbut-2-en-1-ylidene]pyrrolidin-1-amine (**2f''**)

Yellow oil, 65 % yield. ¹H NMR (300 MHz, CDCl₃) δ 7.02 (s, 1H), 5.57 (q, *J* = 6.9 Hz, 1H), 3.65 – 3.59 (m, 1H), 3.49 – 3.42 (m, 2H), 3.40 – 3.37 (m, 4H), 2.90 – 2.79 (m, 1H), 2.00 – 1.84 (m, 4H), 1.83 – 1.81 (m, 3H), 1.76 (dd, *J* = 7.0, 0.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 140.25 (CH), 135.70 (C), 126.33 (CH), 74.85 (CH₂), 63.44 (CH), 59.37 (CH₃), 49.65 (CH₂), 26.90 (CH₂), 22.27 (CH₂), 13.90 (CH₃), 11.46 (CH₃).

Synthesis of (1E,2Z)-3-phenylacrylaldehyde diisopropylhydrazone (**Z-2b**)




Dess-Martin periodinane (1.04 g, 2.46 mmol) was added to a solution of (Z)-3-phenylprop-2-en-1-ol² (300 mg, 2.24 mmol) in CH₂Cl₂ (2.5 ml) and the resulting mixture was stirred for 4h at rt. Then, solutions of NaHCO₃ (1 ml) and H₂S₂O₃ (1 ml) were subsequently added and the resulting mixture was stirred for 15 min. After extraction with CH₂Cl₂ (2 x 5 ml), the combined organic phases were washed with NaCl_{sat} (10 ml), dried and concentrated to provide a crude residue containing the (Z)-3-phenylacrylaldehyde,³ which was subsequently treated with diisopropylhydrazine and MgSO₄ (16h at rt) to provide the hydrazone **Z-2b**, which was obtained in 81% yield after column chromatography. (1E,2E)-3-Phenylacrylaldehyde diisopropylhydrazone (**Z-2b**). ¹H NMR (300 MHz, CDCl₃) δ 7.55 (d, *J* = 9.0 Hz, 1H), 7.40 – 7.30 (m, 4H), 7.27 – 7.17 (m, 1H), 6.48 – 6.31 (m, 2H), 3.82 (hept, *J* = 6.6 Hz, 2H), 1.19 (d, *J* = 6.6 Hz, 12H). ¹³C NMR (75

² Pavlakos E., Georgiou T., Tofi M., Montagnon T., Vassilikogiannakis G. *Org. Lett.* **2009**, *11*, 4556-4559.

³ Fehr C., Magpantay I., Vuagnoux M., Dupau P. *Chem. Eur. J.* **2011**, *17*, 1257-1260

MHz, CDCl₃) δ 138.64 (C), 130.57 (CH), 128.77 (CH), 128.35 (CH), 126.33 (CH), 126.18 (CH), 124.96 (CH), 47.87 (CH), 21.02 (CH₃). **LRMS** (ESI): 231 (M⁺ + 1), 189, 132, 86. **HRMS** calculated for C₁₅H₂₃N₂ 231.1856, found 231.1847.

Experimental procedure for the Au^I-catalyzed [2+2] cycloaddition. Exemplified for the cycloaddition of **1a** and **2a**



The gold complex **Au1** (12.3 mg, 0.016 mmol) was added to a solution of **1a** (40 mg, 0.32 mmol) and **2a** (156 mg, 0.64 mmol) in (CH₂)₂Cl₂ (1.3 ml) at rt. The resulting mixture was stirred for 10 min, filtered through florisil (eluting with CH₂Cl₂) and concentrated. The crude residue was purified on column chromatography (hexanes: EtOAc 7:3) to afford 117 mg of the [2+2] cycloadduct **3aa** (0.32 mmol, 99% yield). (1*R*,2*Z*,4*R*)-1-methyl-2-[(2-oxo-1,3-oxazolidin-3-yl)methylene]-4-phenylcyclobutanecarbaldehyde diisopropylhydrazone (**3aa**). Yellow solid. **¹H NMR** (500 MHz, CDCl₃) δ 7.32 (t, *J* = 7.6 Hz, 2H), 7.25 – 7.20 (m, 1H), 7.14 (d, *J* = 7.9 Hz, 2H), 6.81 (s, 1H), 6.38 (d, *J* = 0.7 Hz, 1H), 4.35 – 4.26 (m, 1H), 4.19 (dd, *J* = 17.2, 8.5 Hz, 1H), 3.91 (td, *J* = 9.0, 5.4 Hz, 1H), 3.82 – 3.73 (m, 2H), 3.68 (t, *J* = 9.4 Hz, 1H), 3.63 – 3.56 (m, 1H), 3.14 (ddd, *J* = 14.3, 10.0, 2.5 Hz, 1H), 2.86 (ddd, *J* = 14.3, 8.6, 1.3 Hz, 1H), 1.14 (d, *J* = 6.5 Hz, 12H), 1.08 (s, 3H). **¹³C NMR** (126 MHz, CDCl₃) δ 156.90 (C), 139.73 (C), 133.91 (CH), 129.06 (C), 128.12 (CH), 127.54 (CH), 126.25 (CH), 116.58 (CH), 62.42 (CH₂), 54.47 (C), 47.26 (CH), 46.87 (CH₂), 45.68 (CH), 29.27 (CH₂), 21.31 (CH₃), 20.38 (CH₃), 18.64 (CH₃). **LRMS** (ESI): 370 (M⁺ + 1), 270, 242, 181, 155, 126; **HRMS** calculated for C₂₂H₃₂N₃O₂ 370.2489, found 370.2481.

In addition to nOe experiments (Figure S1), the structure and stereochemical identity of this adduct could be further corroborated by X-ray analysis (Figure S2).⁴






Figure S1. nOe signals observed for **Z-3aa**. **Figure S2.** X-ray crystal structure of **3aa**

Other products isolated on the preliminary screening of Table 1 (manuscript)

(1*R*,2*Z*,4*R*)-1-Methyl-2-[(2-oxo-1,3-oxazolidin-3-yl)methylene]-4-phenylcyclobutanecarbaldehyde diisopropylhydrazone (**E-3aa**).⁵

⁴ CCDC 1029359 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.



¹H NMR (300 MHz, CDCl₃) δ 7.34 – 7.19 (m, 5H), 6.58 (s, 1H), 6.01 (dd, *J* = 3.0, 2.2 Hz, 1H), 4.33 – 4.24 (m, 2H), 3.86 – 3.67 (m, 5H), 2.94 – 2.82 (m, 1H), 2.69 (ddd, *J* = 15.8, 7.9, 3.1 Hz, 1H), 1.16 (d, *J* = 6.5 Hz, 6H), 1.11 (d, *J* = 6.5 Hz, 6H), 0.97 (s, 3H). **¹³C NMR** (126 MHz, CDCl₃) δ 156.49 (C), 142.59 (C), 140.02 (C), 132.78 (CH), 128.78 (CH), 127.85 (CH), 126.44 (CH), 116.99 (CH), 61.92 (CH₂), 55.17 (C), 54.70 (CH), 47.22 (CH), 45.86 (CH₂), 32.27 (CH₂), 21.36 (CH₃), 20.65 (CH₃), 17.94 (CH₃). **LRMS** (ESI): 370 (M⁺ + 1), 263, 242, 198, 155, 129, 100; **HRMS** calculated for C₂₂H₃₂N₃O₂ 370.2489, found 370.2492.






Figure S3. nOe signals observed for **E-3aa**

3-((1*S*,4*R*,5*R*)-5-((*E*)-(2,2-Diisopropylhydrazone)methyl)-5-methyl-4-phenylcyclopent-2-en-1-yl)oxazolidin-2-one (**4aa**).⁶



NMR H (500 MHz, CDCl₃) δ 6.45 (s, 1H), 6.28 (d, *J* = 5.9 Hz, 1H), 5.78 (dt, *J* = 5.8, 2.8 Hz, 1H), 5.10 (dd, *J* = 4.2, 1.9 Hz, 1H), 4.25 – 4.21 (m, 1H), 4.17 – 4.11 (m, 1H), 3.59 (ddd, *J* = 9.5, 8.5, 6.7 Hz, 2H), 3.49 – 3.39 (m, 2H) 1.22 (d, *J* = 6.5 Hz, 6H), 1.19 (d, *J* = 6.5 Hz, 6H), 0.80 (s, 3H). **¹³C NMR** (126 MHz, CDCl₃) δ 140.08 (C), 130.32 (CH), 128.78 (CH), 128.72 (CH), 127.80 (CH), 126.60 (CH), 126.39 (CH), 68.86 (CH), 62.17 (CH₂), 52.98 (C), 52.78 (CH), 46.90 (CH), 41.71 (CH₂), 24.42 (CH₃), 21.03 (CH₃). **LRMS** (ESI): 370 (M⁺ + 1), 328, 269, 225, 202, 182, 155, 100; **HRMS** calculated for C₂₂H₃₂N₃O₂ 370.2489, found 370.2486.

(1*E*,5*E*)-2-Methylene-6-(2-oxo-1,3-oxazolidin-3-yl)-3-phenylhex-5-enal diisopropylhydrazone (**6aa**).⁷



¹H NMR (500 MHz, CDCl₃) δ 7.30 (d, *J* = 7.2 Hz, 2H), 7.27 – 7.22 (m, 2H), 7.15 (t, *J* = 7.2 Hz, 1H), 6.99 (s, 1H), 6.65 (d, *J* = 14.3 Hz, 1H), 5.06 (d, *J* = 8.8 Hz, 2H), 4.73 (dt, *J* = 14.4, 7.2 Hz, 1H), 4.36 (t, *J* = 8.3 Hz, 2H), 4.18 (t, *J* = 7.8 Hz, 1H), 3.76 (p, *J* = 6.5 Hz, 2H), 3.63 – 3.52 (m, 2H), 2.73 (dt, *J* = 14.3, 7.3 Hz, 1H), 2.58 (dt, *J* = 14.4, 7.3 Hz, 1H), 1.15 (d, *J* = 6.6 Hz, 6H), 1.03 (d, *J* = 6.5 Hz, 6H). **¹³C NMR** (75 MHz, CDCl₃) δ 155.4 (C), 150.0 (C), 144.3 (C), 129.5 (CH), 128.3 (CH), 128.0 (CH), 125.9 (CH), 124.6 (CH), 111.9 (CH₂), 110.1 (CH), 62.0 (CH₂), 47.1 (CH), 46.1 (CH), 42.5 (CH₂), 35.0 (CH₂), 20.9 (CH₃), 20.7 (CH₃). **LRMS** (*m/z*, ESI): 370.25, (M+H)⁺, 283.21, 241.17, 199.12, 182.10, 155.09, 126.06. **HRMS** Calculated for C₂₂H₃₂N₃O₂: 370.2489, found 370.2495.


⁵ a) Isolated from the reactions catalyzed by PtCl₂, PtBr₂, AuCl or PicAuCl₂, Table 1 (main manuscript), entries 1-5). b) As a general trend, besides nOe experiments and X-ray analysis, the assignment of the *Z*/*E* geometry of the exo-enamide moiety could also be carried out on the bases of the ¹H NMR chemical shifts of the enamide and hydrazone signals. We found that *Z* isomers have the enamide and hydrazone signals more deshielded than the corresponding *E* counterparts. In this particular case, chemical shifts for **Z-3aa** are δ = 6.81 ppm (hydrazone) and 6.38 ppm (enamide), whereas for **E-3aa** are 6.58 ppm (hydrazone) and 6.01 ppm (enamide).

⁶ Data deduced from a sample of **4aa** slightly contaminated with **E-3aa** and **5aa** (Table 1, entries 1-3).

⁷ Obtained from the reaction catalyzed by PhPAuNTf₂ (Table 1, entry 6)


Cycloadducts obtained following the general procedure with the catalyst Au1 (Table 2, manuscript)

(1*R*,2*Z*,4*S*)-2-[(2-Oxo-1,3-oxazolidin-3-yl)methylene]-4-phenylcyclobutanecarbaldehyde diisopropylhydrazone (3ab**)**




Yellow solid, 62% yield. ¹H NMR (500 MHz, CDCl₃) δ 7.34 – 7.28 (m, 4H), 7.24 – 7.19 (m, 1H), 6.71 (d, *J* = 6.7 Hz, 1H), 6.40 (q, *J* = 2.2 Hz, 1H), 4.34 – 4.28 (m, 1H), 4.23 – 4.17 (m, 1H), 4.06 (td, *J* = 9.1, 5.4 Hz, 1H), 3.94 (ddd, *J* = 9.4, 6.4, 2.8 Hz, 1H), 3.73 (hept, *J* = 6.5 Hz, 2H), 3.66 (q, *J* = 9.1 Hz, 1H), 3.51 (dt, *J* = 9.3, 7.1 Hz, 1H), 3.19 – 3.12 (m, 1H), 2.81 (ddd, *J* = 15.4, 7.4, 2.4 Hz, 1H), 1.11 (d, *J* = 6.7 Hz, 12H). ¹³C NMR (126 MHz, CDCl₃) δ 156.71 (C), 144.53 (C), 131.12 (CH), 128.49 (CH), 126.52 (CH), 126.30 (CH), 123.51 (C), 118.03 (CH), 62.56 (CH₂), 54.14 (CH), 47.14 (CH), 45.60 (CH₂), 41.84 (CH), 33.73 (CH₂), 20.97 (CH₃), 20.61 (CH₃). LRMS (ESI): 356 (M⁺ + 1), 314, 256, 228, 167, 126, 100; HRMS calculated for C₂₁H₃₀N₃O₂ 356.2333, found 356.2335.

(1*R*,2*S*,4*Z*)-2-(4-Methoxyphenyl)-4-[(2-oxo-1,3-oxazolidin-3-yl)methylene]cyclobutanecarbaldehyde diisopropylhydrazone (3ac**)**




Yellow solid, 88% yield. ¹H NMR (500 MHz, CDCl₃) δ, 7.21 (d, *J* = 8.6 Hz, 2H), 6.85 (d, *J* = 8.6 Hz, 2H), 6.70 (d, *J* = 6.8 Hz, 1H), 6.38 (d, *J* = 2.1 Hz, 1H), 4.30 (td, *J* = 8.9, 5.5 Hz, 1H), 4.19 (q, *J* = 8.5 Hz, 1H), 4.05 (td, *J* = 9.1, 5.4 Hz, 1H), 3.90 – 3.85 (m, 1H), 3.79 (s, 3H), 3.68 (hept, *J* = 6.5 Hz, 2H), 3.65 (q, *J* = 9.0 Hz, 1H), 3.44 (dd, *J* = 16.2, 7.1 Hz, 1H), 3.15 – 3.08 (m, 1H), 2.76 (ddd, *J* = 15.3, 7.4, 2.3 Hz, 1H), 1.12 – 1.07 (m, 12H). ¹³C NMR (126 MHz, CDCl₃) δ 158.12 (C), 156.68 (C), 136.62 (C), 131.33 (CH), 127.48 (CH), 123.60 (C), 117.95 (CH), 113.86 (CH), 62.54 (CH₂), 55.36 (CH₃), 54.35 (CH), 47.12 (CH), 45.59 (CH₂), 41.20 (CH), 33.96 (CH₂), 20.92 (CH₃), 20.58 (CH₃). LRMS (ESI): 386 (M⁺ + 1), 286, 257, 199, 167, 125, 100; HRMS calculated for C₂₂H₃₂N₃O₃ 386.2438, found 386.2437.

(1*R*,2*S*,4*Z*)-2-(4-Fluorophenyl)-4-[(2-oxo-1,3-oxazolidin-3-yl)methylene]cyclobutanecarbaldehyde diisopropylhydrazone (3ad**)**




White solid, 55% yield. ¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.25 (m, 2H), 7.05 – 6.99 (m, 2H), 6.71 (d, *J* = 6.7 Hz, 1H), 6.42 (q, *J* = 2.2 Hz, 1H), 4.37 – 4.31 (m, 1H), 4.22 (dd, *J* = 17.2, 8.5 Hz, 1H), 4.06 (td, *J* = 9.1, 5.4 Hz, 1H), 3.94 – 3.88 (m, 1H), 3.76 (hept, *J* = 6.5 Hz, 2H), 3.69 (q, *J* = 9.2 Hz, 1H), 3.50 (dd, *J* = 16.2, 7.2 Hz, 1H), 3.20 – 3.13 (m, 1H), 2.79 (ddd, *J* = 15.4, 7.5, 2.4 Hz, 1H), 1.13 (dd, *J* = 7.9, 6.6 Hz, 12H). ¹³C NMR (126 MHz, CDCl₃) δ 161.50 (d, *J* = 244.2 Hz, C), 156.70 (C), 140.21 (C), 130.69 (CH), 127.96 (d, *J* = 7.8 Hz, CH), 123.25 (C), 118.17 (CH), 115.22 (d, *J* = 21.2 Hz, CH), 62.57 (CH₂), 54.42 (CH), 47.16 (CH), 45.65 (CH₂), 41.25 (CH), 33.90 (CH₂), 20.96 (CH₃), 20.63 (CH₃). LRMS (ESI): 374 (M⁺ + 1), 274, 249, 207, 167, 126; HRMS calculated for C₂₁H₂₉FN₃O₂ 374.2238, found 374.2242.

(1*S*,2*Z*,4*R*)-2-[(2-Oxo-1,3-oxazolidin-3-yl)methylene]-1,4-diphenylcyclobutanecarbaldehyde diisopropylhydrazone (**Z-3ae**)⁸




Yellow oil. **¹H NMR** (500 MHz, C₆D₆) δ 7.39 (dd, *J* = 8.0, 0.9 Hz, 2H), 7.18 (t, *J* = 7.7 Hz, 2H), 7.12 (s, 1H), 7.09 – 7.03 (m, 2H), 7.02 – 6.95 (m, 4H), 6.31 (s, 1H), 3.67 (t, *J* = 9.0 Hz, 1H), 3.35 – 3.22 (m, 4H), 3.04 – 2.95 (m, 2H), 2.74 (ddd, *J* = 14.9, 9.1, 1.6 Hz, 1H), 2.58 (td, *J* = 9.0, 6.4 Hz, 1H), 0.82 (d, *J* = 6.6 Hz, 6H), 0.77 (d, *J* = 6.4 Hz, 6H). **¹³C NMR** (126 MHz, C₆D₆) δ 156.24 (C), 147.34 (C), 140.12 (C), 128.83 (CH), 128.69 (CH), 128.49 (CH), 128.43 (CH), 128.35 (CH), 127.14 (CH), 126.71 (CH), 120.66 (C), 119.36 (CH), 62.22 (C), 61.74 (CH₂), 53.61 (CH), 47.28 (CH), 45.03 (CH₂), 29.76 (CH₂), 21.22 (CH₃), 20.52 (CH₃). **LRMS** (ESI): 432 (*M*⁺ + 1), 361, 345, 331; **HRMS** calculated for C₂₇H₃₄N₃O₂ 432.2646, found 432.2655.

(1*S*,2*E*,4*R*)-2-[(2-Oxo-1,3-oxazolidin-3-yl)methylene]-1,4-diphenylcyclobutanecarbaldehyde diisopropylhydrazone (**E-3ae**)



Yellow oil. **¹H NMR** (300 MHz, CDCl₃) δ 7.16 – 7.01 (m, 8H), 6.93 (s, 1H), 6.84 (dd, *J* = 7.0, 2.5 Hz, 2H), 6.75 – 6.70 (m, 1H), 4.45 (t, *J* = 9.2 Hz, 1H), 4.20 – 4.07 (m, 2H), 3.82 (dq, *J* = 12.8, 6.4 Hz, 2H), 3.64 (td, *J* = 8.6, 6.8 Hz, 1H), 3.42 (td, *J* = 9.0, 5.5 Hz, 1H), 3.15 – 2.96 (m, 2H), 1.23 – 1.16 (m, 12H). **LRMS** (ESI): 432 (*M*⁺ + 1), 381, 353, 345, 331; **HRMS** calculated for C₂₇H₃₄N₃O₂ 432.2646, found 432.2632.

(1*R*,2*S*,4*Z*)-1,2-Dimethyl-4-[(2-oxo-1,3-oxazolidin-3-yl)methylene]cyclobutanecarbaldehyde diisopropylhydrazone (**Z-3af**)⁹



Yellow oil. **¹H NMR** (500 MHz, CDCl₃) δ 6.59 (s, 1H), 6.18 – 6.16 (m, 1H), 4.26 (ddd, *J* = 9.0, 7.3, 3.7 Hz, 1H), 4.17 – 4.08 (m, 1H), 3.86 (td, *J* = 9.1, 5.5 Hz, 1H), 3.68 (dt, *J* = 13.0, 6.5 Hz, 2H), 3.61 – 3.55 (m, 1H), 2.70 – 2.63 (m, 1H), 2.40 – 2.26 (m, 2H), 1.31 (s, 3H), 1.09 (d, *J* = 6.5 Hz, 6H), 1.05 (d, *J* = 6.5 Hz, 6H), 0.99 (d, *J* = 6.8 Hz, 3H). **¹³C NMR** (126 MHz, CDCl₃) δ 159.96 (C), 135.44 (CH), 130.41 (C), 116.16 (CH), 62.39 (CH₂), 51.96 (C), 47.15 (CH), 46.90 (CH₂), 36.06 (CH), 33.79 (CH₂), 21.00 (CH₃), 20.62 (CH₃), 17.07 (CH₃), 15.04 (CH₃). **LRMS** (ESI): 308 (*M*⁺ + 1), 266, 221, 180, 126, 100;; **HRMS** calculated for C₁₇H₃₀N₃O₂ 308.2333, found 308.2332.





Figure S4. nOe signals observed for **Z-3af**

⁸ The combined yield for the mixture of **Z-3ae** and **E-3ae** is 95% (*Z/E* ratio = 6:4). We could separate a small amount of the *Z* isomer that allowed its independent characterization.

⁹ The combined yield for the mixture of **Z-3af** and **E-3af** is 87% (*Z/E* ratio = 8:2). We could separate a small amount of both isomers that allowed their independent characterization.

(1*R*,2*S*,4*E*)-1,2-Dimethyl-4-[(2-oxo-1,3-oxazolidin-3-yl)methylene]cyclobutanecarbaldehyde diisopropylhydrazone (*E*-**3af**)



Yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 6.47 (s, 1H), 5.83 (s, 1H), 4.30 – 4.19 (m, 2H), 3.81 – 3.75 (m, 1H), 3.74 – 3.64 (m, 3H), 2.46 (ddd, *J* = 15.5, 7.6, 3.2 Hz, 1H), 2.38 – 2.29 (m, 1H), 2.07 – 1.99 (m, 1H), 1.15 (s, 3H), 1.09 (dd, *J* = 8.4, 6.7 Hz, 12H), 0.93 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 156.5 (C), 143.30 (C), 135.21 (CH), 117.68 (CH), 61.94 (CH₂), 53.96 (C), 47.34 (CH), 45.78 (CH₂), 43.53 (CH), 35.90 (CH₂), 21.19 (CH₃), 20.44 (CH₃), 15.91 (CH₃), 13.72 (CH₃). LRMS (ESI): 308 (M⁺ + 1), 266, 221, 180, 126, 100, 86; HRMS calculated for C₁₇H₃₀N₃O₂ 308.2333, found 308.2330.






Figure S5. nOe signals observed for *E*-**3af**.

(1*S*,2*S*,4*Z*)-2-Methyl-4-[(2-oxo-1,3-oxazolidin-3-yl)methylene]-1-phenylcyclobutanecarbaldehyde diisopropylhydrazone (*Z*-**3ag**).¹⁰



Yellow oil. ¹H NMR (300 MHz, CDCl₃) δ 7.43 – 7.38 (m, 2H), 7.36 – 7.29 (m, 2H), 7.24 – 7.17 (m, 1H), 6.96 (s, 1H), 6.53 (t, *J* = 2.0 Hz, 1H), 4.06 – 3.84 (m, 2H), 3.76 (dq, *J* = 12.9, 6.5 Hz, 2H), 3.60 (hept, *J* = 9.4, 1H), 2.99 – 2.80 (m, 2H), 2.65 – 2.51 (m, 1H), 2.30 (ddd, *J* = 14.5, 7.8, 2.4 Hz, 1H), 1.15 (d, *J* = 6.5 Hz, 3H), 1.10 (d, *J* = 6.6 Hz, 12H). ¹³C NMR (75 MHz, CDCl₃) δ 156.72 (C), 147.00 (C), 128.79 (CH), 128.47 (CH), 126.65 (CH), 126.31 (CH), 123.81 (C), 117.45 (CH), 62.56 (CH₂), 59.64 (C), 47.39 (CH), 45.18 (CH₂), 43.73 (CH), 33.46 (CH₂), 21.53 (CH₃), 20.63 (CH₃), 17.00 (CH₃). LRMS (ESI): 370 (M⁺ + 1), 270, 242, 182, 155, 126, 100; HRMS calculated for C₂₂H₃₂N₃O₂ 370.2489, found 370.2485.

(1*S*,2*S*,4*E*)-2-Methyl-4-[(2-oxo-1,3-oxazolidin-3-yl)methylene]-1-phenylcyclobutanecarbaldehyde diisopropylhydrazone (*E*-**3ag**)




Yellow oil. ¹H NMR (300 MHz, CDCl₃) δ 7.36 – 7.19 (m, 5H), 6.92 (s, 1H), 6.08 – 6.05 (m, 1H), 4.12 (t, *J* = 8.0 Hz, 2H), 3.77 (dt, *J* = 13.0, 6.5 Hz, 2H), 3.61 (dd, *J* = 16.4, 8.5 Hz, 1H), 3.26 (dd, *J* = 17.0, 8.2 Hz, 1H), 3.13 (dd, *J* = 16.1, 7.5 Hz, 1H), 2.55 (ddd, *J* = 15.8, 7.7, 3.1 Hz, 1H), 1.95 (ddd, *J* = 15.8, 9.0, 2.1 Hz, 1H), 1.18 – 1.10 (m, 12H), 0.55 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 156.27 (C), 140.32 (C), 132.97 (CH), 128.13 (CH),

¹⁰ The combined yield for the mixture of *Z*-**3ag** and *E*-**3ag** is 94% (*Z/E* ratio = 6:4). We could separate a small amount of both isomers that allowed their independent characterization.

126.51 (CH), 119.31 (CH), 62.34 (CH₂), 61.97 (C), 47.41 (CH), 46.03 (CH₂), 44.20 (CH), 36.18 (CH₂), 21.10 (CH₃), 20.94 (CH₃), 16.63 (CH₃). **LRMS** (ESI): 370 (M⁺ + 1), 328, 283, 242, 198, 155, 126, 100; **HRMS** calculated for C₂₂H₃₂N₃O₂ 370.2489, found 370.2487.

(1*R*,2*S*,4*Z*)-2-Methyl-4-[(2-oxo-1,3-oxazolidin-3-yl)methylene]cyclobutanecarbaldehyde diisopropylhydrazone (**Z-3ah**)



Yellow oil, 95% yield. **¹H NMR** (500 MHz, CDCl₃) δ 6.62 (d, *J* = 6.9 Hz, 1H), 6.27 (t, *J* = 3.7 Hz, 1H), 4.28 (td, *J* = 8.9, 5.5 Hz, 1H), 4.16 (q, *J* = 8.7 Hz, 1H), 4.04 – 3.99 (m, 1H), 3.70 – 3.62 (m, 3H), 3.37 – 3.31 (m, 1H), 2.88 – 2.81 (m, 1H), 2.33 – 2.26 (m, 1H), 2.18 – 2.12 (m, 1H), 1.18 (dd, *J* = 6.8, 2.4 Hz, 3H), 1.07 (d, *J* = 6.6 Hz, 6H), 1.03 (d, *J* = 6.6 Hz, 6H). **¹³C NMR** (126 MHz, CDCl₃) δ 156.53 (C), 133.25 (CH), 123.40 (C), 118.05 (CH), 62.45 (CH₂), 53.35 (CH), 47.07 (CH), 45.28 (CH₂), 34.16 (CH₂), 32.50 (CH), 20.66 (CH₃), 20.65 (CH₃), 20.63 (CH₃). **LRMS** (ESI): 294 (M⁺ + 1), 252, 207, 166, 126; **HRMS** calculated for C₁₆H₂₈N₃O₂ 294.2176, found 294.2179.





Figure S6. nOe signals observed for *E*-**3ah**

(1*R*,6*S*,8*Z*)-8-[(2-Oxo-1,3-oxazolidin-3-yl)methylene]bicyclo[4.2.0]octane-1-carbaldehyde diisopropylhydrazone (**Z-3ai**)¹¹



Yellow oil. **¹H NMR** (500 MHz, CDCl₃) δ 6.50 (s, 1H), 6.14 (s, 1H), 4.26 (td, *J* = 8.9, 5.3 Hz, 1H), 4.13 (q, *J* = 8.6 Hz, 1H), 3.85 (td, *J* = 9.1, 5.3 Hz, 1H), 3.70 (hept, *J* = 6.5 Hz, 2H), 3.50 (q, *J* = 9.1 Hz, 1H), 2.65 – 2.54 (m, 2H), 2.47 (ddd, *J* = 14.0, 8.8, 0.7 Hz, 1H), 2.42 – 2.34 (m, 1H), 1.64 – 1.39 (m, 6H), 1.28 – 1.18 (m, 1H), 1.09 (d, *J* = 6.6 Hz, 6H), 1.08 (d, *J* = 6.5 Hz, 6H). **¹³C NMR** (126 MHz, CDCl₃) δ 157.03 (C), 133.41 (CH), 131.89 (C), 115.15 (CH), 62.47 (CH₂), 50.93 (C), 47.19 (CH), 47.11 (CH₂), 36.70 (CH), 29.93 (CH₂), 29.24 (CH₂), 25.33 (CH₂), 21.56 (CH₂), 21.16 (CH₃), 21.08 (CH₂), 20.64 (CH₃). **LRMS** (ESI): 334 (M⁺ + 1), 292, 247, 206, 162, 119, 100; **HRMS** calculated for C₁₉H₃₂N₃O₂ 334.2489, found 334.2493.





Figure S7. nOe signals observed for *Z*-**3ai**


¹¹ The combined yield for the mixture of *Z*-**3ai** and *E*-**3ai** is 90% (*Z*/*E* ratio = 7:3). We could separate a small amount of both isomers that allowed their independent characterization.

(1*R*,6*S*,8*E*)-8-[(2-Oxo-1,3-oxazolidin-3-yl)methylene]bicyclo[4.2.0]octane-1-carbaldehyde diisopropylhydrazone (**E-3ai**)




Yellow oil. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 6.42 (s, 1H), 5.75 (s, 1H), 4.28 – 4.16 (m, 2H), 3.85 (ddd, $J = 9.0, 7.9, 4.7$ Hz, 1H), 3.74 – 3.59 (m, 3H), 2.45 – 2.37 (m, 2H), 2.33 – 2.27 (m, 2H), 1.61 – 1.56 (m, 1H), 1.54 – 1.33 (m, 6H), 1.11 – 1.07 (m, 12H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 156.40 (C), 144.85 (C), 133.64 (CH), 117.41 (CH), 61.92 (CH_2), 52.85 (C), 47.23 (CH), 45.85 (CH_2), 44.63 (CH), 32.21 (CH_2), 30.92 (CH_2), 25.96 (CH_2), 21.64 (CH_2), 21.48 (CH_2), 21.13 (CH_3), 20.74 (CH_3). **LRMS** (ESI): 334 ($\text{M}^+ + 1$), 292, 247, 206, 162, 119, 100; **HRMS** calculated for $\text{C}_{19}\text{H}_{32}\text{N}_3\text{O}_2$ 334.2489, found 334.2491.

5-[(2*E*)-3-(2-Oxo-1,3-oxazolidin-3-yl)prop-2-en-1-yl]cyclopent-1-ene-1-carbaldehyde diisopropylhydrazone (**6aj**)



Yellow oil, 65% yield, $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.16 (s, 1H), 6.65 (d, $J = 14.6$ Hz, 1H), 5.59 (s, 1H), 4.80 (dt, $J = 14.6, 7.5$ Hz, 1H), 4.43 – 4.38 (m, 2H), 3.83 – 3.75 (m, 2H), 3.69 (dd, $J = 8.8, 7.4$ Hz, 2H), 3.14 – 3.07 (m, 1H), 2.56 (dddd, $J = 13.7, 7.3, 3.3, 1.1$ Hz, 1H), 2.41 – 2.26 (m, 2H), 2.24 – 2.17 (m, 1H), 1.97 (ddd, $J = 17.1, 12.9, 9.1$ Hz, 1H), 1.75 – 1.67 (m, 1H), 1.14 (d, $J = 6.5$ Hz, 12H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 155.53 (C), 146.10 (C), 127.09 (CH), 125.67 (CH), 124.38 (CH), 110.45 (CH), 62.18 (CH_2), 47.12 (CH), 44.25 (CH), 42.84 (CH_2), 33.64 (CH_2), 31.46 (CH_2), 28.75 (CH_2), 21.22 (CH_3), 20.96 (CH_3). **LRMS** (ESI): 320 ($\text{M}^+ + 1$), 278, 233, 191, 126; **HRMS** calculated for $\text{C}_{18}\text{H}_{30}\text{N}_3\text{O}_2$ 320.2333, found 320.2332.


Ethyl (1*S*,2*R*,3*Z*/*E*)-2-[(*E*)-(diisopropylhydrazone)methyl]-2-methyl-3-[(2-oxo-1,3-oxazolidin-3-yl)methylene]cyclobutanecarboxylate (**3ak**).¹²



Yellow oil, 83% yield. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 6.60 (s, 0.62H), 6.50 (s, 0.38H), 6.26 (d, $J = 2.0$ Hz, 0.62H), 5.76 (dd, $J = 2.8, 2.2$ Hz, 0.38H), 4.32 – 4.03 (m, 4H), 3.82 (td, $J = 9.1, 5.6$ Hz, 0.62H), 3.78 – 3.66 (m, 2.8H), 3.56 (dd, $J = 17.3, 9.1$ Hz, 0.62H), 3.32 (dd, $J = 9.3, 8.6$ Hz, 0.38H), 3.18 – 3.07 (m, 1.24H), 2.83 (ddd, $J = 16.3, 9.6, 2.0$ Hz, 0.38H), 2.60 (ddd, $J = 14.5, 7.9, 1.4$ Hz, 0.62H), 2.48 (ddd, $J = 16.2, 8.3, 3.1$ Hz, 0.38H), 1.39 (s, 2H), 1.26 (s, 1H), 1.24 – 1.18 (m, 3H), 1.13 – 1.06 (m, 12H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 172.56 (C), 172.00 (C), 156.58 (C), 156.55 (C), 132.74 (CH), 132.03 (CH), 126.85 (C), 117.15 (CH), 115.94 (CH), 62.24 (CH_2), 61.84 (CH_2), 60.31 (CH_2), 60.23 (CH_2), 54.03 (CH), 53.72 (C), 47.20 (CH_2), 47.17 (CH_2), 45.77 (CH_2), 44.73 (CH), 29.61 (CH_2), 27.17 (CH_2), 21.21 (CH_3), 21.13 (CH_3), 20.36 (CH_3), 20.22 (CH_3), 18.69 (CH), 17.73 (CH), 14.38 (CH_3), 14.26 (CH_3). **LRMS** (ESI): 366, 324, 279, 238, 181, 164, 126; **HRMS** calculated for $\text{C}_{19}\text{H}_{32}\text{N}_3\text{O}_4$ 366.2386, found 366.2387.


¹² *Z* and *E* isomers of **3ak** could not be separated by standard column chromatography techniques.

(1*R*,2*Z*,4*R*)-1-Methyl-2-[(2-oxo-1,3-oxazolidin-3-yl)methylene]-4-phenylcyclobutanecarbaldehyde dimethylhydrazone (**3aa'**)




Yellow solid, 76% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.29 (q, $J = 7.3$ Hz, 2H), 7.21 (t, $J = 7.3$ Hz, 1H), 7.12 (d, $J = 7.6$ Hz, 2H), 6.85 (s, 1H), 6.36 (s, 1H), 4.33 – 4.20 (m, 2H), 3.86 – 3.78 (m, 1H), 3.68 (t, $J = 9.4$ Hz, 1H), 3.57 (dd, $J = 16.9, 9.0$ Hz, 1H), 3.13 – 3.10 (m, 1H), 2.87 (dd, $J = 14.6, 8.8$ Hz, 1H), 2.79 (s, 6H), 1.05 (s, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 156.78 (C), 141.58 (CH), 139.19 (C), 128.16 (CH), 127.93 (C), 127.60 (CH), 126.45 (CH), 117.07 (CH), 62.19 (CH_2), 53.42 (C), 46.74 (CH_2), 45.29 (CH), 43.37 (CH_3), 29.35 (CH_2), 18.58 (CH_3). **LRMS** (CI): 314.1 ($\text{M}^+ + 1$), 227, 182, 126. **HRMS** calculated for $\text{C}_{18}\text{H}_{24}\text{N}_3\text{O}_2$ 314.1869, found 314.1860.

(1*E*,5*E*)-2-Methylene-6-(2-oxo-1,3-oxazolidin-3-yl)-3-phenylhex-5-enal dimethylhydrazone (**6aa'**)




6% yield. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.35 – 7.27 (m, 4H), 7.23 – 7.16 (m, 1H), 6.94 (s, 1H), 6.68 (d, $J = 14.3$ Hz, 1H), 5.22 (s, 1H), 5.21 (s, 1H), 4.75 (dt, $J = 14.3, 7.2$ Hz, 1H), 4.36 (t, $J = 8.1$ Hz, 2H), 4.17 (t, $J = 7.8$ Hz, 1H), 3.61 – 3.54 (m, 2H), 2.85 (s, 6H), 2.81 – 2.70 (m, 1H), 2.67 – 2.57 (m, 1H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 155.39 (C), 148.79 (C), 143.79 (C), 134.93 (CH), 128.30 (CH), 128.06 (CH), 126.01 (CH), 124.71 (CH), 114.29 (CH_2), 109.74 (CH), 62.10 (CH_2), 45.95 (CH), 42.69 (CH_3), 42.58 (CH_2), 34.75 (CH_2). **LRMS** (ESI): 314 ($\text{M}^+ + 1$), 182, 111. **HRMS** calculated for $\text{C}_{18}\text{H}_{24}\text{N}_3\text{O}_2$ 314.1869, found 314.1875.

(1*R*,2*Z*,4*S*)-2-[(2-Oxo-1,3-oxazolidin-3-yl)methylene]-4-phenylcyclobutanecarbaldehyde dimethylhydrazone (**3ab'**)



Yellow oil, 53% yield. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.26 – 7.19 (m, 4H), 7.16 – 7.11 (m, 1H), 6.66 (d, $J = 7.2$ Hz, 1H), 6.33 (q, $J = 2.3$ Hz, 1H), 4.27 – 4.16 (m, 2H), 3.91 – 3.83 (m, 2H), 3.59 (dd, $J = 16.9, 9.2$ Hz, 1H), 3.45 – 3.40 (m, 1H), 3.13 – 3.06 (m, 1H), 2.80 – 2.73 (m, 1H), 2.69 (s, 6H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 156.61 (C), 143.77 (C), 137.81 (CH), 128.53 (CH), 126.58 (CH), 126.52 (CH), 122.12 (C), 118.60 (CH), 62.43 (CH_2), 53.30 (CH), 45.57 (CH_2), 43.18 (CH_3), 41.81 (CH), 34.13 (CH_2). **LRMS** (CI): 300.1 ($\text{M}^+ + 1$), 255, 213, 126, 111. **HRMS** calculated for $\text{C}_{17}\text{H}_{22}\text{N}_3\text{O}_2$ 300.1712, found 300.1714.

(1*R*,2*S*,4*Z*)-2-(4-Methoxyphenyl)-4-[(2-oxo-1,3-oxazolidin-3-yl)methylene]cyclobutanecarbaldehyde dimethylhydrazone (**3ac'**)



Yellow solid, 41% yield. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.25 – 7.21 (m, 2H), 6.90 – 6.87 (m, 2H), 6.75 (d, $J = 7.3$ Hz, 1H), 6.44 – 6.41 (m, 1H), 4.38 – 4.26 (m, 2H), 3.99 – 3.94 (m, 1H), 3.93 – 3.88 (m, 1H), 3.81 (s, 3H), 3.69 (dd, $J = 17.0, 9.2$ Hz, 1H), 3.49 – 3.43 (m, 1H), 3.20 – 3.13 (m, 1H), 2.85 – 2.80 (m, 1H), 2.79 (s, 6H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 158.35 (C), 156.68 (C), 138.23 (CH), 135.94 (C), 127.64 (CH), 122.36 (C), 118.58 (CH), 113.99 (CH), 62.48 (CH_2), 55.43 (CH), 53.61 (CH), 45.66 (CH_2), 43.26 (CH_3), 41.28 (CH_3), 34.46 (CH_2). **LRMS** (CI): 330.1 ($\text{M}^+ + 1$), 286, 243, 198, 111, 88. **HRMS** calculated for $\text{C}_{18}\text{H}_{24}\text{N}_3\text{O}_3$ 329.1818, found 330.1819. In addition to nOe experiments, the

structure and stereochemical identity of this adduct could be further corroborated by X-ray analysis (Figure S8).¹³






Figure S8. X-ray structure of **3ac'**

(1*R*,2*S*,4*Z*/*E*)-1,2-Dimethyl-4-[(2-oxo-1,3-oxazolidin-3-yl)methylene]cyclobutanecarbaldehyde dimethylhydrazone (**3af'**)




White solid, 47% yield.¹⁴ **¹H NMR** (500 MHz, CDCl₃) δ 6.70 (s, 0.18H), 6.65 (s, 0.82H), 6.25 (t, *J* = 2.0 Hz, 0.18H), 6.19 (t, *J* = 1.9 Hz, 0.82H), 4.32 – 4.19 (m, 2H), 3.81 – 3.63 (m, 2H), 3.61 – 3.55 (m, 2H), 2.74 (s, 1.08H), 2.72 (s, 4.92H), 2.42 – 2.29 (m, 2H), 1.43 (s, 0.54H), 1.31 (s, 2.46H), 1.03 (d, *J* = 7.0 Hz, 0.54H), 1.00 (d, *J* = 6.8 Hz, 2.46H). **¹³C NMR** (101 MHz, CDCl₃) δ 156.90, 142.47, 129.35, 117.79, 116.60, 62.24, 50.90, 46.80, 43.54, 43.39, 35.74, 33.80, 33.16, 24.53, 17.03, 16.86, 14.94, 13.61. **LRMS** (CI): 252.1 (*M*⁺ + 1), 207, 165, 126, 116, 88. **HRMS** calculated for C₁₃H₂₂N₃O₂ 252.1712, found 251.1710.

3-((*E*)-5-((*E*)-(2,2-dimethylhydrazone)methyl)-4-methylhexa-1,5-dien-1-yl)oxazolidin-2-one (**6af'**)



White solid. 21% yield. **¹H NMR** (500 MHz, CDCl₃) δ 6.95 (s, 1H), 6.61 (d, *J* = 14.3 Hz, 1H), 5.08 – 5.04 (m, 2H), 4.80 – 4.73 (m, 1H), 4.43 – 4.37 (m, 2H), 3.67 (dd, *J* = 14.7, 6.1 Hz, 2H), 2.95 – 2.87 (m, 1H), 2.84 (s, 6H), 2.38 – 2.29 (m, 1H), 2.19 – 2.09 (m, 1H), 1.07 (dd, *J* = 7.0, 0.8 Hz, 3H). **¹³C NMR** (126 MHz, CDCl₃) δ 155.53 (C), 150.89 (C), 136.17 (CH), 124.58 (CH), 113.52 (CH₂), 110.05 (CH), 62.19 (CH₂), 42.93 (CH₃), 42.80 (CH₂), 36.32 (CH₂), 34.04 (CH), 19.43 (CH₃). **LRMS** (CI): 252.1 (*M*⁺ + 1), 207, 180, 165, 126, 59. **HRMS** calculated for C₁₃H₂₂N₃O₂ 252.1712, found 251.1711.

Ethyl (1*S*,2*R*,*Z*)-2-((*E*)-(2,2-dimethylhydrazone)methyl)-2-methyl-3-((2-oxooxazolidin-3-yl)methylene)cyclobutane-1-carboxylate (**3ak'**)




Yellow oil, 63% yield. **¹H NMR** (500 MHz, CDCl₃) δ 6.66 (s, 1H), 6.29 – 6.27 (m, 1H), 4.34 – 4.22 (m, 2H), 4.20 – 4.11 (m, 2H), 3.83 – 3.77 (m, 1H), 3.60 – 3.54 (m, 1H), 3.21 – 3.10 (m, 3H), 2.77 (s, 6H), 2.69 – 2.63 (m, 1H), 1.39 (s, 3H), 1.25 (t, *J* = 7.1 Hz, 3H). **¹³C NMR** (126 MHz, CDCl₃) δ 171.92 (C), 156.72 (C), 139.48 (CH), 126.33 (C), 117.88 (CH),

¹³ CCDC 1029358 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

¹⁴ *Z* : *E* ratio = 0.93 : 0.07, (¹H NMR of the crude mixture) *Z* : *E* ratio = 0.82 : 0.18 after column chromatography. The isomers could not be separated.


62.24 (CH₂), 60.70 (CH₂), 52.73 (C), 46.64 (CH₂), 44.45 (CH), 43.24 (CH₃), 27.42 (CH₂), 18.89 (CH₃), 14.56 (CH₃). **LRMS** (CI): 310 (M⁺ + 1), 299.1, 223.1, 126.1, 88.0. **HRMS** calculated for C₁₅H₂₄N₃O₄ 310.1767 found 310.1768.

3-((Z)-((2R,3R)-2-((E)-(((S)-2-(methoxymethyl)pyrrolidin-1-yl)imino)methyl)-2-methyl-3-phenylcyclobutylidene)methyl)oxazolidin-2-one (**3aa''**)




Yellow oil, 85% yield, *dr* = 7 : 3. **¹H NMR** (500 MHz, CDCl₃) δ 7.38 – 7.28 (m, 2H), 7.24 (t, *J* = 7.3 Hz, 1H), 7.18 – 7.14 (m, 2H), 6.87 (s, 0.7H), 6.83 (s, 0.3H), 6.39 (s, 0.7H), 6.38 (s, 0.3H), 4.38 – 4.22 (m, 3H), 4.01 – 3.87 (m, 2H), 3.75 – 3.66 (m, 1H), 3.64 – 3.54 (m, 2H), 3.53 – 3.45 (m, 2H), 3.44 – 3.40 (m, 1H), 3.39 (s, 2.1H), 3.36 (s, 0.9H), 3.19 – 3.11 (m, 0.3H), 2.91 – 2.82 (m, 0.7H), 2.08 – 1.92 (m, 2.8H), 1.90 – 1.80 (m, 1.2H), 1.07 (s, 2.1H), 1.04 (s, 0.9H). **¹³C NMR** (126 MHz, CDCl₃) δ 141.36 (CH), 141.00 (CH), 139.37 (C), 128.57 (C), 128.14 (CH), 128.02 (C), 127.90 (C), 127.72 (C), 127.66 (CH), 126.43 (CH), 116.99 (CH), 74.78 (CH₂), 74.55 (CH₂), 63.35 (CH₃), 62.35 (CH₂), 62.21 (CH₂), 59.69 (CH), 59.53 (CH), 53.60 (C), 46.82 (CH₂), 46.79 (CH₂), 45.66, 45.28, 29.33 (CH₂), 29.25 (CH₂), 26.72 (CH₂), 26.55 (CH₂), 22.23 (CH₂), 22.12 (CH₂), 18.88 (CH₃), 18.75 (CH₃). **LRMS** (ESI): 384 (M⁺ + 1), 297, 270, 242, 195, 155, 129; **HRMS** calculated for C₂₂H₃₀N₃O₃ 384.2282, found 384.2270.

3-((Z)-((2R,3S)-2-((E)-(((S)-2-(methoxymethyl)pyrrolidin-1-yl)imino)methyl)-2,3-dimethylcyclobutylidene)methyl)oxazolidin-2-one (**3af''**)



Yellow oil, 63% yield, *dr* = 6 : 4. **¹H NMR** (500 MHz, CDCl₃) δ 6.66 (s, 0.6H), 6.60 (s, 0.4H), 6.20 – 6.18 (m, 1H), 4.33 – 4.09 (m, 2H), 3.92 – 3.81 (m, 2H), 3.62 – 3.53 (m, 3H), 3.45 – 3.39 (m, 1H), 3.36 (s, 1.8H), 3.34 (s, 1.2H), 2.77 – 2.66 (m, 2H), 2.43 – 2.27 (m, 2H), 2.00 – 1.85 (m, 3H), 1.83 – 1.74 (m, 1H), 1.30 (s, 1.8H), 1.30 (s, 1.2H), 1.00 (d, *J* = 6.8 Hz, 3H). **¹³C NMR** (75 MHz, CDCl₃) δ 156.85 (C), 142.44 (CH), 141.61 (CH), 129.64 (C), 129.06 (C), 116.48 (CH), 74.87 (CH₂), 74.59 (CH₂), 63.49 (CH₃), 63.35 (CH₃), 62.31 (CH₂), 62.15 (CH₂), 59.32 (CH), 59.21 (CH), 51.07 (C), 50.06 (C), 49.83 (CH₂), 46.88 (CH₂), 46.73 (CH₂), 35.84 (CH), 35.70 (CH), 33.68 (CH₂), 26.71 (CH₂), 26.58 (CH₂), 22.24 (CH₂), 22.19 (CH₂), 17.11 (CH₃), 14.99 (CH₃), 14.92 (CH₃). **LRMS** (ESI): 321 (M⁺ + 1), 235, 180, 126; **HRMS** calculated for C₁₇H₂₇N₃O₃ 321.2125, found 321.2131.

N-((Z)-((2R,3R)-2-((E)-(2,2-diisopropylhydrazono)methyl)-2-methyl-3-phenylcyclobutylidene)methyl)-4-methyl-*N*-phenylbenzenesulfonamide (**3ba**)



95% yield. **¹H NMR** (300 MHz, CDCl₃) δ 7.47 (d, *J* = 8.2 Hz, 2H), 7.35 – 7.15 (m, 10H), 7.12 – 7.04 (m, 2H), 6.78 (s, 1H), 6.19 – 6.16 (m, 1H), 3.98 (t, *J* = 9.1 Hz, 1H), 3.81 – 3.68 (m, 2H), 3.03 (ddd, *J* = 14.6, 9.6, 2.3 Hz, 1H), 2.95 – 2.83 (m, 1H), 2.44 (s, *J* = 8.1 Hz, 3H), 1.23 (d, *J* = 6.5 Hz, 6H), 1.13 (d, *J* = 6.4 Hz, 6H), 0.51 (s, 3H). **¹³C NMR** (75 MHz, CDCl₃) δ 144.40 (C), 143.69 (C), 142.61 (C), 140.32 (C), 134.34 (C), 133.04 (CH), 129.44 (CH), 128.60 (CH), 127.92 (CH), 127.81 (CH), 127.66 (CH), 126.85 (CH), 125.94 (CH), 119.32 (CH), 55.19 (C), 47.01 (CH), 43.19 (CH), 29.30 (CH₂), 21.68 (CH₃), 21.41 (CH₃), 20.43 (CH₃), 17.01 (CH₃).

LRMS (ESI): 530, 457, 381, 353; **HRMS** calculated for C₃₂H₄₀N₃O₂S₂ 530.2836, found 530.2835.






Figure S9. nOe signals observed for **3ba**

N-((*Z*)-{(2*R*,3*S*)-2-[(*E*)-(diisopropylhydrazone)methyl]-3-phenylcyclobutylidene)methyl)-4-methyl-*N*-phenylbenzenesulfonamide (**3bb**)




(1*R*,4*R*,*Z*)-1-Methyl-2-((2-oxooxazolidin-3-yl)methylene)-4-phenylcyclobutane-1-carbonitrile (**7a**).



Magnesium monoperoxyphthalate (MMPP, 73.6 mg, 1.49 mmol) was added to a solution of **3aa** (50 mg, 0.14 mmol) in EtOH (2 ml) at 0°C. After stirring for 5 min, a solution of Na₂SO₃ (sat) (2 ml) was added and the mixture was extracted with CH₂Cl₂ (2 x 5 ml). The combined organic phases were subsequently washed with NaHCO₃ (5 ml) and NaCl (5 ml), dried and concentrated to afford a crude residue that was purified on column chromatography (hexanes:Et₂O = 9:1), to yield 23.3 mg of **7a** (64 % yield). **¹H NMR** (300 MHz, CDCl₃) δ 7.47 – 7.31 (m, 3H), 7.30 – 7.24 (m, 2H), 6.54 (dd, *J* = 5.7, 3.6 Hz, 1H), 4.52 – 4.43 (m, 2H), 4.39 – 4.29 (m, 1H), 4.21 (t, *J* = 9.6 Hz, 1H), 3.96 – 3.86 (m, 1H), 3.27 (ddd, *J* = 15.1, 10.0, 2.5 Hz, 1H), 3.02 (ddd, *J* = 15.1, 9.3, 1.6 Hz, 1H), 1.25 (s, 3H). **¹³C NMR** (75 MHz, CDCl₃) δ 156.28 (C), 136.11 (C), 128.81 (CH), 127.94 (CH), 127.88 (CH), 123.97 (C), 119.73 (CH), 117.49 (C), 62.32 (CH₂), 45.61 (CH₂), 45.33 (CH), 40.33 (C), 29.59 (CH₂), 21.42 (CH₃). **LRMS** (CI): 268 (M⁺). **HRMS** calculated for C₁₆H₁₇N₂O₂ 268.1212, found 268.1205.

(1R,2S,5S,6R)-5-Methyl-6-phenyl-3-oxabicyclo[3.2.0]heptane-1,2-diol (**9a**)



HCl 1M (0.16 ml, 1.37 mmol) was added to a solution of **3aa'** (50 mg, 1.37 mmol) in Et₂O (2.3 ml) and the mixture was stirred for 5 min at rt. The mixture was poured into brine (10 ml), extracted with Et₂O and dried. The solvent was removed under reduced pressure and the crude residue was chromatographed on silica gel (hexanes:Et₂O 8:2), to yield 39 mg of the corresponding aldehyde (90 % yield). (1R,4R,Z)-1-methyl-2-((2-oxooxazolidin-3-yl)methylene)-4-phenylcyclobutane-1-carbaldehyde. ¹H NMR (500 MHz, CDCl₃) δ 9.88 (s, 1H), 7.36 (t, *J* = 7.6 Hz, 2H), 7.31 – 7.26 (m, 1H), 7.12 (d, *J* = 7.4 Hz, 2H), 6.57 (t, *J* = 2.0 Hz, 1H), 4.35 (t, *J* = 8.0 Hz, 2H), 3.98 (t, *J* = 9.1 Hz, 1H), 3.65 – 3.54 (m, 2H), 3.32 (ddd, *J* = 15.1, 9.1, 2.4 Hz, 1H), 3.06 (ddd, *J* = 15.2, 9.2, 1.6 Hz, 1H), 1.04 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 200.78 (CH), 156.33 (C), 137.49 (C), 128.49 (CH), 127.94 (CH), 127.14 (CH), 119.88 (CH), 119.29 (C), 62.08 (CH₂), 60.65 (C), 45.28 (CH₂), 39.96 (CH), 30.46 (CH₂), 15.81 (CH₃). LRMS (ESI): 271 (M⁺ + 1); HRMS calculated for C₁₆H₁₇NO₃ 271.1208, found 271.1204

NaBH₄ (0.013 g, 0.350 mmol) was added to a solution of (Z)-1-methyl-2-((2-oxooxazolidin-3-yl)methylene)-4-phenylcyclobutanecarbaldehyde (38 mg, 0.140 mmol) in MeOH (2 ml). After stirring at rt for 5 min, acetone and water were successively added to the reaction mixture. After extraction with Et₂O (3 x 5 ml) the combined organic phases were dried and evaporated to afford a crude residue that was chromatographed (hexanes/EtOAc, 1:1) to give **8a** (29.2 mg, 0.107 mmol, 76 % yield). 3-((Z)-((2R,3R)-2-(hydroxymethyl)-2-methyl-3-phenylcyclobutylidene)methyl)oxazolidin-2-one (**8a**). ¹H NMR (300 MHz, CDCl₃) δ 7.36 – 7.27 (m, 2H), 7.25 – 7.14 (m, 3H), 5.99 (t, *J* = 2.1 Hz, 1H), 4.45 – 4.30 (m, 2H), 3.86 – 3.65 (m, 4H), 3.63 – 3.54 (m, 1H), 3.15 (t, *J* = 6.4 Hz, 1H), 3.09 – 2.85 (m, 2H), 0.78 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 158.08 (C), 139.99 (C), 139.21 (C), 128.11 (CH), 127.97 (CH), 126.31 (CH), 116.94 (CH), 68.57 (CH₂), 62.24 (CH₂), 53.90 (C), 46.83 (CH₂), 40.36 (CH), 29.03 (CH₂), 18.16 (CH₃). LRMS (*m/z*, ESI): 269.13 (M+Na)⁺, 256.13, 212.14, 169.10, 154.08, 105.05. HRMS Calculated for C₁₆H₁₉NNaO₃: 296.1257, found 296.1258.

H₂O (141 μl), NMO (21.43 mg, 0.183 mmol) and OsO₄ (4%wt solution in H₂O, 29.1 μl, 4.57 μmol) were added successively to a stirred solution of (Z)-3-((2-(hydroxymethyl)-2-methyl-3-phenylcyclobutylidene)methyl)oxazolidin-2-one (25 mg, 0.091 mmol) in acetone:acetonitrile 1:1 (0.3mL). After being stirred at rt for 3h, the reaction mixture was quenched with Na₂S₂O₃ sat (2 ml) and further stirred for 30 min. After extraction with CH₂Cl₂, the organic phases were dried and evaporated to afford a crude residue that was chromatographed (hexanes/EtOAc 10-50%) to give **9a** (12.2 mg 61% yield). (1R,2S,5S,6R)-5-methyl-6-phenyl-3-oxabicyclo[3.2.0]heptane-1,2-diol (**9a**). ¹H NMR (500 MHz, CDCl₃) δ 7.32 (t, *J* = 7.5 Hz, 2H), 7.25 – 7.17 (m, 3H), 5.39 (s, 1H), 3.93 (d, *J* = 8.9 Hz, 1H), 3.84 (d, *J* = 8.9 Hz, 1H), 3.48 (s, 1H), 3.17 (t, *J* = 9.2 Hz, 1H), 3.12 (s, 1H), 2.60 (dd, *J* = 12.9, 9.6 Hz, 1H), 2.45 (dd, *J* = 12.9, 8.9 Hz, 1H), 1.67 (s, 1H), 0.72 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 140.09 (C), 128.12 (CH), 127.87 (CH), 126.30 (CH), 100.35

(CH), 78.90 (C), 77.47 (CH₂), 51.94 (C), 39.41 (CH), 32.05 (CH₂), 11.68 (CH₃). (ESI): 243.1 (M+ Na), 173.1, 131.1, 105.1. **HRMS** Calculated for C₁₃H₁₆NaO₃: 243.0992, found 243.0986.









Figure S10. nOe signals observed for **9a**





Studies on the stereospecificity of the process. Cycloaddition between 1a and Z-2b




The cycloaddition of the **Z-2b** provided the same cycloadduct (**Z-3ab**) than that obtained from **E-2b**. A potential isomerization of the hydrazone (**Z-2a**) to the more stable **E**-counterpart during the reaction could be ruled out by submitting the hydrazone **Z-2b** to the reaction conditions, in the absence of the allenamide: after 5h, **Z-2b** had not been converted to the **E**-counterpart (**E-3ab**) and could be recovered or, alternatively, if allenamide **1a** was added, the cycloadduct **Z-3ab** was obtained in good yield. Moreover, analysis of this reaction by ¹H-NMR at different conversions did not show the presence of **E-2b** in the reaction media.

NMR SPECTRA








r






Z-2b










2c
















2d




























































































































Z-3ai













***E*-3ai**





















6aa'
























Z : E = 0.82 : 0.18
























7a

